Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.

Gynecologic oncology - 1 Sept 2021

Kuroda Yuka, Chiyoda Tatsuyuki, Kawaida Miho, Nakamura Kohei, Aimono Eriko, Yoshimura Takuma, Takahashi Mio, Saotome Keiko, Yoshihama Tomoko, Iwasa Naomi, Sakai Kensuke, Yamagami Wataru, Nishihara Hiroshi, Aoki Daisuke

Abstract excerpt

OBJECTIVES: ARID1A mutation is frequently found in clear cell ovarian cancer (CCC) and endometrioid ovarian cancer (EC). Anti-PD-1 monotherapy has been found to have limited efficacy in epithelial ovarian cancer; however, anti-PD-1 therapy showed significant clinical benefit in some CCC. We sought to define the relationship of ARID1A mutation/ARID1A expression to the immunogenic profile of different histologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Ovarian Epithelial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to DNA-Binding Proteins

Share to Gene Expression Regulation, Neoplastic

Share to Neoplasms, Cystic, Mucinous, and Serous

Share to Ovarian Neoplasms

Share to Transcription Factors

Source

Identifiers

PMID: 34272091
DOI: 10.1016/j.ygyno.2021.07.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.PMID 34272091Read ↗

Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.Semantic proximity Read ↗

Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin.Semantic proximity Read ↗

Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.Semantic proximity Read ↗

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian CarcinomaSemantic proximity Read ↗

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.Semantic proximity Read ↗

Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.Semantic proximity Read ↗

Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovarySemantic proximity Read ↗

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Semantic proximity Read ↗

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.Semantic proximity Read ↗

Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinomaSemantic proximity Read ↗

Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.